New K V 7.2/3 Channel Activators Exhibit Superior Toxicity and Metabolic Profiles to Flupirtine and Demonstrate Promising In Vivo Analgesic Effects
ACS Chemical Neuroscience · 2025
DOI: 10.1021/acschemneuro.5c00278 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Chemical Neuroscience, 2025. Verfasst von Frieda-Marie Bartz und 9 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pharmacy, Department of Pharmaceutical and Medicinal Chemistry, University of Greifswald, Friedrich-Ludwig-Jahn-Str. 17, Greifswald 1748…. Hauptthemen laut MEDLINE: Analgesics, Aminopyridines, KCNQ2 Potassium Channel, KCNQ3 Potassium Channel. Die Arbeit nennt 71 Literaturangaben. Gefördert von: Deutsche Forschungsgemeinschaft.
Abstract (Originalsprache)
The first-in-class KV7.2/3 channel activator flupirtine, was considered a potent analgesic in various pain conditions. However, it was withdrawn from the market in 2018 due to severe hepatotoxicity associated with forming reactive metabolites. In this work, we present new KV7.2/3 channel modulators that have been evaluated in several preclinical mouse pain models, including acute thermally and chemically induced pain, diabetes-induced neuropathic pain, and chemotherapy-induced peripheral neuropathy. In addition, the new KV7.2/3 channel activators were compared with the reference substances flupirtine, retigabine, and azetukalner, focusing on the inhibition of the hERG channel, nephrotoxicity, metabolic stability, and the formation of reactive metabolites. A flupirtine analog with a pyrimidine scaffold (8) showed clear advantages over the reference compounds tested, with a favorable toxicity profile, a 2 h in vitro half-life when incubated with human liver microsomes, and a 9-fold reduction in the formation of reactive metabolites compared to flupirtine. This compound also demonstrated strong in vivo efficacy in pain models, making it a promising candidate for further development of KV7.2/3 channel activators.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Pharmacy, Department of Pharmaceutical and Medicinal Chemistry, University of Greifswald, Friedrich-Ludwig-Jahn-Str. 17, Greifswald 17489, Germany.
- Faculty of Pharmacy, Chair of Pharmacodynamics, Jagiellonian University Medical College, 9 Medyczna St., Krakow 30-688, Poland.
ORCID-Profile: Jana Lemke, Louis Schmidt, Lukas Schulig, Andreas Link, Patrick J Bednarski
Förderung
- Deutsche Forschungsgemeinschaft
Zitieren
APA
Bartz, F. M., Sałat, K., Urbańska, K., Lemke, J., Rosendahl, P., Schmidt, L., Schulig, L., Garscha, U., Link, A., & Bednarski, P. J. (2025). New K V 7.2/3 Channel Activators Exhibit Superior Toxicity and Metabolic Profiles to Flupirtine and Demonstrate Promising In Vivo Analgesic Effects. ACS Chemical Neuroscience. https://doi.org/10.1021/acschemneuro.5c00278
Vancouver
Bartz FM, Sałat K, Urbańska K, Lemke J, Rosendahl P, Schmidt L, et al. New K V 7.2/3 Channel Activators Exhibit Superior Toxicity and Metabolic Profiles to Flupirtine and Demonstrate Promising In Vivo Analgesic Effects. ACS Chemical Neuroscience. 2025. doi:10.1021/acschemneuro.5c00278
BibTeX
@article{Bartz2025,
author = {Bartz, Frieda-Marie and Sałat, Kinga and Urbańska, Katarzyna and Lemke, Jana and Rosendahl, Pascal and Schmidt, Louis and Schulig, Lukas and Garscha, Ulrike and Link, Andreas and Bednarski, Patrick J},
title = {New K V 7.2/3 Channel Activators Exhibit Superior Toxicity and Metabolic Profiles to Flupirtine and Demonstrate Promising In Vivo Analgesic Effects},
journal = {ACS Chemical Neuroscience},
year = {2025},
doi = {10.1021/acschemneuro.5c00278}
}
EUVIMED